Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer

Author(s): Tianhong Li, Primo N. Lara Jr., Philip C. Mack, Roman Perez-Soler, David R. Gandara, Gert van Assche, Severine Vermeire, Paul Rutgeerts

Journal Name: Current Drug Targets

Volume 11 , Issue 1 , 2010

Become EABM
Become Reviewer
Call for Editor


Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.

Keywords: Pemetrexed, multi-targeted antifolate, erlotinib, small molecule tyrosine kinase inhibitor (TKI), epidermal growth factor receptor (EGFR), non-small cell lung cancer (NSCLC), Mucosal healing, endoscopy, medical therapy, IBD, Crohn's disease, ulcerative colitis

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [85 - 94]
Pages: 10
DOI: 10.2174/138945010790030983

Article Metrics

PDF: 26